- Home
- SKYT vs XERS Comparison
SKYT vs XERS Comparison
Compare SKYT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYT | XERS |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SKYT | XERS |
|---|---|---|
| Price | $29.26 | $6.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $26.50 | $10.43 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 02-25-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $346,587,000.00 | $266,137,000.00 |
| Revenue This Year | $28.48 | $44.77 |
| Revenue Next Year | $41.29 | $27.72 |
| P/E Ratio | $11.17 | ★ N/A |
| Revenue Growth | 0.19 | ★ 42.05 |
| 52 Week Low | $5.67 | $3.51 |
| 52 Week High | $36.27 | $10.08 |
Technical Indicators
Market Signals| Indicator | SKYT | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 39.45 |
| Support Level | $28.13 | $6.78 |
| Resistance Level | $30.87 | $7.26 |
| Average True Range (ATR) | 1.62 | 0.30 |
| MACD | -0.80 | -0.05 |
| Stochastic Oscillator | 21.80 | 4.60 |
Price Performance
Historical ComparisonAbout SKYT SkyWater Technology Inc.
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).